868 related articles for article (PubMed ID: 16226444)
1. Growing roles for the mTOR pathway.
Sarbassov DD; Ali SM; Sabatini DM
Curr Opin Cell Biol; 2005 Dec; 17(6):596-603. PubMed ID: 16226444
[TBL] [Abstract][Full Text] [Related]
2. mTOR-what does it do?
Hall MN
Transplant Proc; 2008 Dec; 40(10 Suppl):S5-8. PubMed ID: 19100909
[TBL] [Abstract][Full Text] [Related]
3. [PI3K-AKT-mTOR pathway inhibitors].
Cortot A; Armand JP; Soria JC
Bull Cancer; 2006 Jan; 93(1):19-26. PubMed ID: 16455502
[TBL] [Abstract][Full Text] [Related]
4. Insulin and amino-acid regulation of mTOR signaling and kinase activity through the Rheb GTPase.
Avruch J; Hara K; Lin Y; Liu M; Long X; Ortiz-Vega S; Yonezawa K
Oncogene; 2006 Oct; 25(48):6361-72. PubMed ID: 17041622
[TBL] [Abstract][Full Text] [Related]
5. Estrogen-induced activation of mammalian target of rapamycin is mediated via tuberin and the small GTPase Ras homologue enriched in brain.
Yu J; Henske EP
Cancer Res; 2006 Oct; 66(19):9461-6. PubMed ID: 17018601
[TBL] [Abstract][Full Text] [Related]
6. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA
Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
[TBL] [Abstract][Full Text] [Related]
8. Novel role of the small GTPase Rheb: its implication in endocytic pathway independent of the activation of mammalian target of rapamycin.
Saito K; Araki Y; Kontani K; Nishina H; Katada T
J Biochem; 2005 Mar; 137(3):423-30. PubMed ID: 15809346
[TBL] [Abstract][Full Text] [Related]
9. 2-Arylthiazolidine-4-carboxylic acid amides (ATCAA) target dual pathways in cancer cells: 5'-AMP-activated protein kinase (AMPK)/mTOR and PI3K/Akt/mTOR pathways.
Li CM; Narayanan R; Lu Y; Hurh E; Coss CC; Barrett CM; Miller DD; Dalton JT
Int J Oncol; 2010 Oct; 37(4):1023-30. PubMed ID: 20811725
[TBL] [Abstract][Full Text] [Related]
10. Expanding mTOR signaling.
Yang Q; Guan KL
Cell Res; 2007 Aug; 17(8):666-81. PubMed ID: 17680028
[TBL] [Abstract][Full Text] [Related]
11. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells.
Sekulić A; Hudson CC; Homme JL; Yin P; Otterness DM; Karnitz LM; Abraham RT
Cancer Res; 2000 Jul; 60(13):3504-13. PubMed ID: 10910062
[TBL] [Abstract][Full Text] [Related]
12. Development of LanthaScreen cellular assays for key components within the PI3K/AKT/mTOR pathway.
Carlson CB; Robers MB; Vogel KW; Machleidt T
J Biomol Screen; 2009 Feb; 14(2):121-32. PubMed ID: 19196698
[TBL] [Abstract][Full Text] [Related]
13. Nutrient sensing in the mTOR/S6K1 signalling pathway.
Gulati P; Thomas G
Biochem Soc Trans; 2007 Apr; 35(Pt 2):236-8. PubMed ID: 17371247
[TBL] [Abstract][Full Text] [Related]
14. mTOR and Akt signaling in cancer: SGK cycles in.
Toker A
Mol Cell; 2008 Jul; 31(1):6-8. PubMed ID: 18614042
[TBL] [Abstract][Full Text] [Related]
15. Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, insulin growth factor-I, and serum.
Wlodarski P; Kasprzycka M; Liu X; Marzec M; Robertson ES; Slupianek A; Wasik MA
Cancer Res; 2005 Sep; 65(17):7800-8. PubMed ID: 16140948
[TBL] [Abstract][Full Text] [Related]
16. mTOR, Akt, S6 kinases and the control of skeletal muscle growth.
Pende M
Bull Cancer; 2006 May; 93(5):E39-43. PubMed ID: 16777616
[TBL] [Abstract][Full Text] [Related]
17. TSC1-2 tumour suppressor and regulation of mTOR signalling: linking cell growth and proliferation?
Findlay GM; Harrington LS; Lamb RF
Curr Opin Genet Dev; 2005 Feb; 15(1):69-76. PubMed ID: 15661536
[TBL] [Abstract][Full Text] [Related]
18. LY303511 (2-piperazinyl-8-phenyl-4H-1-benzopyran-4-one) acts via phosphatidylinositol 3-kinase-independent pathways to inhibit cell proliferation via mammalian target of rapamycin (mTOR)- and non-mTOR-dependent mechanisms.
Kristof AS; Pacheco-Rodriguez G; Schremmer B; Moss J
J Pharmacol Exp Ther; 2005 Sep; 314(3):1134-43. PubMed ID: 15923340
[TBL] [Abstract][Full Text] [Related]
19. hvps34, an ancient player, enters a growing game: mTOR Complex1/S6K1 signaling.
Nobukuni T; Kozma SC; Thomas G
Curr Opin Cell Biol; 2007 Apr; 19(2):135-41. PubMed ID: 17321123
[TBL] [Abstract][Full Text] [Related]
20. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma.
Peponi E; Drakos E; Reyes G; Leventaki V; Rassidakis GZ; Medeiros LJ
Am J Pathol; 2006 Dec; 169(6):2171-80. PubMed ID: 17148679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
